Premium
Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: Primary breakpoints and clinical correlations
Author(s) -
Calasanz María J.,
Cigudosa Juan C.,
Odero María D.,
Ferreira Carmen,
Ardanaz M. Teresa,
Fraile Aurora,
Carrasco José L.,
Solé Françesc,
Cuesta Braulia,
Gullón Arturo
Publication year - 1997
Publication title -
genes, chromosomes and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.754
H-Index - 119
eISSN - 1098-2264
pISSN - 1045-2257
DOI - 10.1002/(sici)1098-2264(199702)18:2<84::aid-gcc2>3.0.co;2-x
Subject(s) - multiple myeloma , karyotype , plasma cell leukemia , breakpoint , plasma cell , bone marrow , waldenstrom macroglobulinemia , pathology , macroglobulinemia , plasma cell myeloma , chromosomal translocation , medicine , chronic lymphocytic leukemia , biology , chromosome , gastroenterology , leukemia , genetics , lymphoma , gene
Cytogenetic analysis of unstimulated short‐term bone marrow cell cultures was performed on 280 patients with multiple myeloma and related disorders. In 65% of the cases, an additional short term B‐cell stimulated culture was also examined. Chromosomally abnormal clones were found in 31% of the patients, 15% in Waldenström macroglobulinemia, 25% in monoclonal gammopathies, 33% in multiple myeloma, and 50% in plasma cell leukemia. Three primary chromosomal breakpoints were recurrently involved: 14q32, 16q22, and 22q11. Structural rearrangements of chromosome I were the most frequent (26% of the abnormal cases), but always as a secondary change. Rearrangements of band 14q32 were found in 22% of the abnormal cases. Among the multiple myeloma patients who showed an abnormal karyotype, 33 (46%) were hyperdiploid, most frequently with 52–56 chromosomes, 29 patients (40%) were pseudodiploid, and the remaining 12 cases (14%) were hypodiploid. A highly significant relation was observed between the presence of an abnormal karyotype and the following clinical parameters: stage III ( P = 0.0001), bone marrow plasma cell infiltration greater than 30% ( P = 0.0001), presence of bone lesions ( P = 0.0009), and β2‐microglobulin levels greater than 4 mg/L ( P = 0.0001). Genes Chromosom. Cancer 18:84–93, 1997. © 1997 Wiley‐Liss, Inc.